# Biomarker Tracking Sheet - Peptide Therapy

**For Healthcare Practitioners**

---

## Patient Information

**Patient Name:** ___________________________  
**Date of Birth:** ___________________________  
**Protocol Start Date:** ___________________________  
**Peptide(s):** ___________________________

---

## Vital Signs Tracking

| Date | Weight (lbs/kg) | BMI | BP (mmHg) | HR (bpm) | Notes |
|------|----------------|-----|-----------|----------|-------|
| Baseline | | | | | |
| Week 2 | | | | | |
| Week 4 | | | | | |
| Week 8 | | | | | |
| Week 12 | | | | | |
| Week 16 | | | | | |
| Week 20 | | | | | |
| Week 24 | | | | | |

---

## Comprehensive Metabolic Panel (CMP)

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **Glucose** | 70-100 mg/dL | | | | | |
| **BUN** | 7-20 mg/dL | | | | | |
| **Creatinine** | 0.7-1.3 mg/dL | | | | | |
| **eGFR** | >60 mL/min | | | | | |
| **Sodium** | 136-145 mEq/L | | | | | |
| **Potassium** | 3.5-5.0 mEq/L | | | | | |
| **Chloride** | 98-107 mEq/L | | | | | |
| **CO2** | 23-29 mEq/L | | | | | |
| **Calcium** | 8.5-10.5 mg/dL | | | | | |
| **Total Protein** | 6.0-8.3 g/dL | | | | | |
| **Albumin** | 3.5-5.0 g/dL | | | | | |
| **AST** | 10-40 U/L | | | | | |
| **ALT** | 7-56 U/L | | | | | |
| **Alkaline Phosphatase** | 44-147 U/L | | | | | |
| **Total Bilirubin** | 0.1-1.2 mg/dL | | | | | |

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Complete Blood Count (CBC)

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **WBC** | 4.5-11.0 K/uL | | | | | |
| **RBC** | M: 4.7-6.1, F: 4.2-5.4 M/uL | | | | | |
| **Hemoglobin** | M: 14-18, F: 12-16 g/dL | | | | | |
| **Hematocrit** | M: 42-52%, F: 37-47% | | | | | |
| **MCV** | 80-100 fL | | | | | |
| **MCH** | 27-31 pg | | | | | |
| **MCHC** | 32-36 g/dL | | | | | |
| **Platelets** | 150-400 K/uL | | | | | |
| **Neutrophils** | 40-70% | | | | | |
| **Lymphocytes** | 20-40% | | | | | |
| **Monocytes** | 2-8% | | | | | |
| **Eosinophils** | 1-4% | | | | | |
| **Basophils** | 0.5-1% | | | | | |

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Lipid Panel

| Test | Reference Range | Baseline | Week 12 | Week 24 | Notes |
|------|----------------|----------|---------|---------|-------|
| **Total Cholesterol** | <200 mg/dL | | | | |
| **LDL Cholesterol** | <100 mg/dL | | | | |
| **HDL Cholesterol** | M: >40, F: >50 mg/dL | | | | |
| **Triglycerides** | <150 mg/dL | | | | |
| **VLDL** | 5-40 mg/dL | | | | |
| **Total/HDL Ratio** | <5.0 | | | | |

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Glucose Metabolism

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **Fasting Glucose** | 70-100 mg/dL | | | | | |
| **HbA1c** | <5.7% | | | | | |
| **Fasting Insulin** | 2-20 uIU/mL | | | | | |
| **HOMA-IR** | <2.0 | | | | | |

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Thyroid Panel

| Test | Reference Range | Baseline | Week 12 | Week 24 | Notes |
|------|----------------|----------|---------|---------|-------|
| **TSH** | 0.5-5.0 uIU/mL | | | | |
| **Free T3** | 2.3-4.2 pg/mL | | | | |
| **Free T4** | 0.8-1.8 ng/dL | | | | |
| **Reverse T3** | 9-27 ng/dL | | | | |

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Growth Hormone Axis (for GH Secretagogue Therapy)

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **IGF-1** | Age-adjusted (see chart) | | | | | |
| **IGFBP-3** | Age-adjusted | | | | | |

**IGF-1 Age-Adjusted Reference Ranges:**
- 20-30 years: 115-307 ng/mL
- 30-40 years: 90-260 ng/mL
- 40-50 years: 75-212 ng/mL
- 50-60 years: 65-180 ng/mL
- 60-70 years: 55-165 ng/mL
- >70 years: 45-145 ng/mL

**Target:** Mid-normal range for age

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Inflammatory Markers

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **CRP (high-sensitivity)** | <1.0 mg/L | | | | | |
| **ESR** | M: <15, F: <20 mm/hr | | | | | |
| **IL-6** | <5 pg/mL | | | | | |
| **TNF-alpha** | <8.1 pg/mL | | | | | |

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## GLP-1 Agonist Specific Monitoring

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **Lipase** | 13-60 U/L | | | | | |
| **Amylase** | 30-110 U/L | | | | | |
| **Calcitonin** | <10 pg/mL | | | | | |

**GI Symptom Score (0-10):**
- Baseline: ___________
- Week 1: ___________
- Week 2: ___________
- Week 4: ___________
- Week 8: ___________
- Week 12: ___________

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Immune Function (for Immune Modulator Therapy)

| Test | Reference Range | Baseline | Week 4 | Week 8 | Week 12 | Week 24 |
|------|----------------|----------|--------|--------|---------|---------|
| **IgG** | 700-1600 mg/dL | | | | | |
| **IgA** | 70-400 mg/dL | | | | | |
| **IgM** | 40-230 mg/dL | | | | | |
| **CD4 Count** | 500-1200 cells/uL | | | | | |
| **CD8 Count** | 200-900 cells/uL | | | | | |
| **CD4/CD8 Ratio** | >1.0 | | | | | |

**Infection Frequency:**
- Baseline (past 6 months): ___________
- During therapy: ___________

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Body Composition (DEXA or Bioimpedance)

| Measurement | Baseline | Week 12 | Week 24 | Change | Notes |
|-------------|----------|---------|---------|--------|-------|
| **Total Body Fat %** | | | | | |
| **Lean Mass (kg)** | | | | | |
| **Fat Mass (kg)** | | | | | |
| **Visceral Fat Area (cm²)** | | | | | |
| **Bone Density (T-score)** | | | | | |

**Goals:**
- Fat mass: ↓ ___________ kg
- Lean mass: ↑ ___________ kg or maintain

---

## Cognitive Testing (for Cognitive Enhancement Therapy)

| Test | Reference Range | Baseline | Week 8 | Week 12 | Week 24 | Notes |
|------|----------------|----------|--------|---------|---------|-------|
| **MoCA** | ≥26/30 | | | | | |
| **MMSE** | ≥24/30 | | | | | |
| **GAD-7 (Anxiety)** | <5 (minimal) | | | | | |
| **PHQ-9 (Depression)** | <5 (minimal) | | | | | |

**Subjective Cognitive Assessment (0-10):**
- Focus: ___________
- Memory: ___________
- Processing Speed: ___________
- Mental Clarity: ___________

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Pain & Functional Assessment (for Tissue Repair Therapy)

| Assessment | Baseline | Week 2 | Week 4 | Week 8 | Week 12 | Week 24 |
|------------|----------|--------|--------|--------|---------|---------|
| **VAS Pain Scale (0-10)** | | | | | | |
| **Range of Motion (degrees)** | | | | | | |
| **Grip Strength (kg)** | | | | | | |
| **Gait Speed (m/s)** | | | | | | |
| **DASH Score (upper extremity)** | | | | | | |
| **LEFS Score (lower extremity)** | | | | | | |

**Imaging Results:**
- Baseline: ___________________________
- Follow-up: ___________________________

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Longevity Biomarkers (for Anti-Aging Therapy)

| Test | Reference Range | Baseline | Month 6 | Month 12 | Month 24 | Notes |
|------|----------------|----------|---------|----------|----------|-------|
| **Telomere Length** | Age-adjusted | | | | | |
| **Epigenetic Age** | <Chronological age | | | | | |
| **NAD+ Levels** | Age-adjusted | | | | | |

**Functional Testing:**
- Grip Strength: ___________
- Chair Stand Test: ___________
- Gait Speed: ___________
- Balance Test: ___________

**Abnormal Values & Actions:**
- ___________________________
- ___________________________

---

## Adverse Event Tracking

| Date | Adverse Event | Severity (Mild/Moderate/Severe) | Action Taken | Resolution |
|------|---------------|--------------------------------|--------------|------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

---

## Clinical Notes & Observations

**Week 2:**
___________________________

**Week 4:**
___________________________

**Week 8:**
___________________________

**Week 12:**
___________________________

**Week 24:**
___________________________

---

## Protocol Adjustments Based on Biomarkers

| Date | Biomarker Trigger | Adjustment Made | Rationale |
|------|-------------------|-----------------|-----------|
| | | | |
| | | | |
| | | | |

---

## Summary & Recommendations

**Overall Biomarker Trends:**
☐ Improving as expected  
☐ Stable (no change)  
☐ Concerning trends requiring intervention

**Key Findings:**
- ___________________________
- ___________________________
- ___________________________

**Recommendations:**
☐ Continue current protocol  
☐ Adjust dosing (specify): ___________________________  
☐ Add monitoring (specify): ___________________________  
☐ Discontinue therapy due to: ___________________________

**Practitioner Signature:** ___________________________  
**Date:** ___________________________

---

**Template Version:** 1.0  
**Last Updated:** November 29, 2025  
**Source:** DrsPeptides.com

**For Healthcare Practitioner Use Only**
